secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001558370-25-008525
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Harmony Biosciences Presents Preclinical Data for BP1.15205 OX2R Agonist in Narcolepsy
--------------------------------------------------------------------------------

- Data presented at SLEEP 2025 showed significant wake-promoting and cataplexy-suppressing effects in transgenic mouse model of narcolepsy type 1.
- BP1.15205 demonstrated high potency (EC50=0.015 nM) and >600-fold selectivity over human OX1R.
- No adverse events were observed in 3-month GLP toxicity study at doses up to 300 mg/kg/day.
- First-in-human study planned for 2H 2025 with topline data anticipated in 2026.
- IMPD application with EMA being completed; IND for BP1.15205 to be filed with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025008525/0001558370-25-008525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025008525/hrmy-20250611x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer